Header Logo

Connection

MURALI CHINTAGUMPALA to Brain Neoplasms

Back to Details
This is a "connection" page, showing publications MURALI CHINTAGUMPALA has written about Brain Neoplasms.
MURALI CHINTAGUMPALA
Connection Strength
6.005
Brain Neoplasms
  1. Treatment age and neurocognitive outcomes following proton beam radiotherapy for pediatric low- and intermediate-grade gliomas. Pediatr Blood Cancer. 2021 08; 68(8):e29096.
    View in: PubMed
    Score: 0.385
  2. Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy. Neuro Oncol. 2019 05 06; 21(5):686-695.
    View in: PubMed
    Score: 0.334
  3. Progression-free survival of children with localized ependymoma treated with intensity-modulated radiation therapy or proton-beam radiation therapy. Cancer. 2017 Jul 01; 123(13):2570-2578.
    View in: PubMed
    Score: 0.288
  4. Advances in Management of Pediatric Ependymomas. Curr Oncol Rep. 2015 Oct; 17(10):47.
    View in: PubMed
    Score: 0.261
  5. Brain tumors. Pediatr Clin North Am. 2015 Feb; 62(1):167-78.
    View in: PubMed
    Score: 0.249
  6. Intensity-modulated radiotherapy (IMRT) in pediatric low-grade glioma. Cancer. 2013 Jul 15; 119(14):2654-9.
    View in: PubMed
    Score: 0.220
  7. Long-term outcome of centrally located low-grade glioma in children. Cancer. 2013 Jul 15; 119(14):2630-8.
    View in: PubMed
    Score: 0.220
  8. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol. 2009 Feb; 11(1):33-40.
    View in: PubMed
    Score: 0.160
  9. Changes mimicking new leptomeningeal disease after intensity-modulated radiotherapy for medulloblastoma. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):214-21.
    View in: PubMed
    Score: 0.156
  10. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neurooncol. 2006 Apr; 77(2):193-8.
    View in: PubMed
    Score: 0.135
  11. Genetic susceptibility to cognitive decline following craniospinal irradiation for pediatric central nervous system tumors. Neuro Oncol. 2023 09 05; 25(9):1698-1708.
    View in: PubMed
    Score: 0.113
  12. Prognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience. J Neurooncol. 2023 Jul; 163(3):717-726.
    View in: PubMed
    Score: 0.112
  13. Circulating tumor DNA sequencing of pediatric solid and brain tumor patients: An institutional feasibility study. Pediatr Hematol Oncol. 2023; 40(8):719-738.
    View in: PubMed
    Score: 0.111
  14. Superior verbal learning and memory in pediatric brain tumor survivors treated with proton versus photon radiotherapy. Neuropsychology. 2023 Feb; 37(2):204-217.
    View in: PubMed
    Score: 0.107
  15. Quantifying the risk and dosimetric variables of symptomatic brainstem injury after proton beam radiation in pediatric brain tumors. Neuro Oncol. 2022 09 01; 24(9):1571-1581.
    View in: PubMed
    Score: 0.105
  16. Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children's Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials. Acta Neuropathol. 2022 10; 144(4):733-746.
    View in: PubMed
    Score: 0.105
  17. Predicting neurocognitive function in pediatric brain tumor early survivorship: The neurological predictor scale and the incremental validity of tumor size. Pediatr Blood Cancer. 2022 09; 69(9):e29803.
    View in: PubMed
    Score: 0.104
  18. A Prospective Evaluation of Fatigue in Pediatric Brain Tumor Patients Treated With Radiation Therapy. J Pediatr Hematol Oncol Nurs. 2022 Nov-Dec; 39(6):358-365.
    View in: PubMed
    Score: 0.104
  19. Cognitive predictors of social adjustment in pediatric brain tumor survivors treated with photon versus proton radiation therapy. Pediatr Blood Cancer. 2022 06; 69(6):e29645.
    View in: PubMed
    Score: 0.102
  20. Spatial Dissection of Invasive Front from Tumor Mass Enables Discovery of Novel microRNA Drivers of Glioblastoma Invasion. Adv Sci (Weinh). 2021 12; 8(23):e2101923.
    View in: PubMed
    Score: 0.099
  21. Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an NTRK2 Fusion: The Impact of Integrated Genomic Profiling. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.098
  22. Long-term cognitive and academic outcomes among pediatric brain tumor survivors treated with proton versus photon radiotherapy. Pediatr Blood Cancer. 2021 09; 68(9):e29125.
    View in: PubMed
    Score: 0.097
  23. Cognitive Risk in Survivors of Pediatric Brain Tumors. J Clin Oncol. 2021 06 01; 39(16):1718-1726.
    View in: PubMed
    Score: 0.096
  24. Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors. Cancer Lett. 2020 11 28; 493:197-206.
    View in: PubMed
    Score: 0.092
  25. Provider views on perioperative steroid use for patients with newly diagnosed pediatric brain tumors. J Neurooncol. 2020 Mar; 147(1):205-212.
    View in: PubMed
    Score: 0.088
  26. Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathol. 2020 02; 139(2):259-271.
    View in: PubMed
    Score: 0.087
  27. Effect of sensorineural hearing loss on neurocognitive and adaptive functioning in survivors of pediatric embryonal brain tumor. J Neurooncol. 2020 Jan; 146(1):147-156.
    View in: PubMed
    Score: 0.087
  28. Cognitive mediators of adaptive functioning outcomes in survivors of pediatric brain tumors treated with proton radiotherapy. Pediatr Blood Cancer. 2020 02; 67(2):e28064.
    View in: PubMed
    Score: 0.087
  29. Germline POLE mutation in a child with hypermutated medulloblastoma and features of constitutional mismatch repair deficiency. Cold Spring Harb Mol Case Stud. 2019 10; 5(5).
    View in: PubMed
    Score: 0.086
  30. Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma. J Clin Oncol. 2020 01 01; 38(1):43-50.
    View in: PubMed
    Score: 0.086
  31. Prospective, longitudinal comparison of neurocognitive change in pediatric brain tumor patients treated with proton radiotherapy versus surgery only. Neuro Oncol. 2019 06 10; 21(6):809-818.
    View in: PubMed
    Score: 0.084
  32. Adaptive functioning in pediatric brain tumor survivors: An examination of ethnicity and socioeconomic status. Pediatr Blood Cancer. 2019 09; 66(9):e27800.
    View in: PubMed
    Score: 0.084
  33. Attention, processing speed, and executive functioning in pediatric brain tumor survivors treated with proton beam radiation therapy. Radiother Oncol. 2017 07; 124(1):89-97.
    View in: PubMed
    Score: 0.073
  34. Mixed neuronal-glial tumors (gangliogliomas) in children. Pediatr Neurosurg. 1996 Jun; 24(6):306-13.
    View in: PubMed
    Score: 0.068
  35. Preservation of KIT genotype in a novel pair of patient-derived orthotopic xenograft mouse models of metastatic pediatric CNS germinoma. J Neurooncol. 2016 05; 128(1):47-56.
    View in: PubMed
    Score: 0.067
  36. Comparing Intelligence Quotient Change After Treatment With Proton Versus Photon Radiation Therapy for Pediatric Brain Tumors. J Clin Oncol. 2016 Apr 01; 34(10):1043-9.
    View in: PubMed
    Score: 0.067
  37. Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients. J Neurooncol. 2015 Nov; 125(2):307-15.
    View in: PubMed
    Score: 0.065
  38. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015 Aug 20; 33(24):2646-54.
    View in: PubMed
    Score: 0.064
  39. Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):47-53.
    View in: PubMed
    Score: 0.064
  40. Imaging Changes in Pediatric Intracranial Ependymoma Patients Treated With Proton Beam Radiation Therapy Compared to Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):54-63.
    View in: PubMed
    Score: 0.063
  41. Silencing BMI1 eliminates tumor formation of pediatric glioma CD133+ cells not by affecting known targets but by down-regulating a novel set of core genes. Acta Neuropathol Commun. 2014 Dec 20; 2:160.
    View in: PubMed
    Score: 0.062
  42. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma. Neuro Oncol. 2013 Sep; 15(9):1173-85.
    View in: PubMed
    Score: 0.055
  43. Maternal variation in EPHX1, a xenobiotic metabolism gene, is associated with childhood medulloblastoma: an exploratory case-parent triad study. Pediatr Hematol Oncol. 2012 Nov; 29(8):679-85.
    View in: PubMed
    Score: 0.053
  44. Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). J Neurooncol. 2012 Sep; 109(3):565-71.
    View in: PubMed
    Score: 0.052
  45. Outcome of patients with pilocytic astrocytoma and leptomeningeal dissemination. Int J Radiat Oncol Biol Phys. 2012 Oct 01; 84(2):350-4.
    View in: PubMed
    Score: 0.051
  46. Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. Radiat Oncol. 2011 Jun 02; 6:58.
    View in: PubMed
    Score: 0.048
  47. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro Oncol. 2011 Jan; 13(1):14-27.
    View in: PubMed
    Score: 0.046
  48. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro Oncol. 2010 Jun; 12(6):580-94.
    View in: PubMed
    Score: 0.044
  49. Medulloblastoma and juvenile pilocytic astrocytoma presenting as synchronous primary brain tumors in a child: case report. J Neurosurg Pediatr. 2010 Feb; 5(2):149-54.
    View in: PubMed
    Score: 0.044
  50. Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells. 2008 Jun; 26(6):1414-24.
    View in: PubMed
    Score: 0.039
  51. Radiation-induced malignant gliomas: is there a role for reirradiation? Int J Radiat Oncol Biol Phys. 2008 Aug 01; 71(5):1381-7.
    View in: PubMed
    Score: 0.038
  52. Intensity-modulated radiation therapy in childhood ependymoma. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):987-93.
    View in: PubMed
    Score: 0.038
  53. Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival. J Neurooncol. 2008 Jan; 86(2):183-90.
    View in: PubMed
    Score: 0.037
  54. FOXG1 dysregulation is a frequent event in medulloblastoma. J Neurooncol. 2007 Nov; 85(2):111-22.
    View in: PubMed
    Score: 0.037
  55. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol. 2006 Feb; 76(3):313-9.
    View in: PubMed
    Score: 0.033
  56. A homozygous mutation in MSH6 causes Turcot syndrome. Clin Cancer Res. 2005 Jul 01; 11(13):4689-93.
    View in: PubMed
    Score: 0.032
  57. Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. Cancer Res. 2005 Jan 01; 65(1):76-84.
    View in: PubMed
    Score: 0.031
  58. White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol. 2004 Nov 15; 22(22):4551-60.
    View in: PubMed
    Score: 0.031
  59. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol. 2004 Aug 15; 22(16):3357-65.
    View in: PubMed
    Score: 0.030
  60. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer. 2003 May 01; 97(9 Suppl):2374-80.
    View in: PubMed
    Score: 0.028
  61. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res. 2002 Jul; 8(7):2202-9.
    View in: PubMed
    Score: 0.026
  62. Primary malignant rhabdoid tumor of the central nervous system. Ultrastruct Pathol. 1997 Jul-Aug; 21(4):361-8.
    View in: PubMed
    Score: 0.018
  63. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. Ultrastruct Pathol. 1997 Jul-Aug; 21(4):369-78.
    View in: PubMed
    Score: 0.018
  64. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet. 2015 Mar; 47(3):263-6.
    View in: PubMed
    Score: 0.016
  65. Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system. Int J Radiat Oncol Biol Phys. 2014 Dec 01; 90(5):1143-52.
    View in: PubMed
    Score: 0.015
  66. Extensively necrotic retinoblastoma is associated with high-risk prognostic factors. Arch Pathol Lab Med. 2006 Nov; 130(11):1669-72.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.